PER — Percheron Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$6.09m
- AU$2.07m
- AU$0.15m
Antisense Therapeutics up on U.S. FDA submission for muscular dystrophy drug
Australia Stock Exchange release from ANTISENSE THERAP : PRE_NR Ends: 09:59:58
Australia Stock Exchange release from ANTISENSE THERAP : ATL1102 Toxicology Protocol submitted to US FDA
Australia Stock Exchange release from ANTISENSE THERAP : Entitlement Offer Closing Date Extended
Australia Stock Exchange release from ANTISENSE THERAP : Update - Proposed issue of securities - ANP
Australia Stock Exchange release from ANTISENSE THERAP : Notice of Annual General Meeting/Proxy Form
Australia Stock Exchange release from ANTISENSE THERAP : Change of Director's Interest Notice - CG
Australia Stock Exchange release from ANTISENSE THERAP : Becoming a substantial holder
Australia Stock Exchange release from ANTISENSE THERAP : PRE_NR Ends: 09:53:06
Australia Stock Exchange release from ANTISENSE THERAP : Prospectus
Australia Stock Exchange release from ANTISENSE THERAP : Application for quotation of securities - ANP
Australia Stock Exchange release from ANTISENSE THERAP : Placement and Cleansing Notice
Australia's Antisense Therapeutics falls most in over a year on share placement
Brief: Antisense Therapeutics Says European Medicines Agency Adopts Positive Final Opinion For Drug
Australia Stock Exchange release from ANTISENSE THERAP : Positive PDCO opinion and A$20m Placement
Australia Stock Exchange release from ANTISENSE THERAP : PRE_NR Ends: 12:10:17
Australia Stock Exchange release from ANTISENSE THERAP : Proposed issue of securities - ANP
Australia Stock Exchange release from ANTISENSE THERAP : Investor Presentation
Australia Stock Exchange release from ANTISENSE THERAP : 2021 Annual Report